Philippe Vuagnat

Philippe Vuagnat is a French venture and private-equity investor best known for his long tenure with Sofimac. French corporate filings list him as a director-general and member of the management board of Sofimac Partners / Sofimac Régions, including a director-general mandate at Sofimac Régions from August 2005 to September 2017. Public company-registry sources also show historical representative or board-related roles connected to companies including Dexterite Surgical and CERADROP.

At Sofimac Innovation, he was publicly identified as an investment director / associate director. In 2018 and 2020 financing announcements for Uavia and Vulkam, he spoke for Sofimac Innovation on seed/deeptech investments backed through vehicles such as Emergence Innovation 2. Sofimac Innovation described itself as an AMF-approved independent management company investing in technology startups, with a particular focus on health and digital sectors.

He now appears publicly as an independent “Expert Senior, Ex-SOFIMAC” on the Linksium Grenoble Alpes investment committee. Linksium describes the committee as made up of independent experts from industry, finance, startups, and competitiveness clusters, selected for operational field knowledge in evaluating project durability and impact.

His LinkedIn profile lists current volunteer investment and entrepreneurship roles: member of SATT Linksium Grenoble Alpes’s investment committee since September 2022, entrepreneurship support at Centre d’Entrepreneuriat Lyon Saint-Etienne since January 2021, and prior support/training at Technopole Grand Poitiers from January 2021 to March 2024. Public education details were not found in the sources reviewed.

• Focuses on technology startups where technical differentiation can be translated into market adoption, industrialization, and long-term company building.
• Through Linksium, evaluates projects from Grenoble academic research for technology maturation and business acceleration, including business model development, market potential, financial roadmaps, and de-risking.
• Sofimac Innovation’s disclosed focus included a wide variety of technology sectors, “particularly in the health and digital sectors,” with experienced investor-entrepreneurs.
• Pertinence Invest 2, managed by Sofimac Innovation, targeted deeptech startups arising from or linked to French academic research in engineering sciences, Industry 4.0, digital, energy/resources, chemistry/materials, health, and nutrition.
• In Uavia’s financing, Vuagnat said Uavia had “the potential to become a strategic supplier” to industrial customers, pointing to a preference for technologies that can become core infrastructure for large industrial markets.
• In Vulkam’s financing, he highlighted a “very innovative process” for amorphous-metal parts and the ability to industrialize and deploy customer programs in watchmaking, health, and military-security markets.